首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
【24h】

Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.

机译:肾移植患者移植后淋巴增生性疾病的长期随访:移植后淋巴增生性疾病引起的手术移植耐受性持续时间,白介素18疗程以及再移植结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) can be resolved in many transplant patients by the reduction or cessation of immunosuppression, after which many grafts continue to function as the result of a form of operational tolerance. When graft function deteriorates, retransplantation may be an option. Cytokines such as interleukin (IL)-10 and IL-18 may play a role in PTLD tolerance induction and tumor regression. We report long-term follow-up on the duration of graft tolerance and the course of retransplantation in a series of patients who underwent kidney transplantation and demonstrated PTLD, and in whom we were able to perform IL-18 analyses. RESULTS: Patients were followed for up to 7 years after PTLD diagnosis. Treatment consisted of immunosuppression cessation with radiation therapy in cases with overt monomorphic lymphomas. All patients' PTLDs were resolved, and all patients but one (whose graft was removed) demonstrated a period of operational graft tolerance of up to 5 years. Five patients underwent retransplantation without sign of recurrence of the PTLD up to 3 years after transplantation. In the eight patients analyzed, IL-18 increased significantly during PTLD regression and follow-up in those with long-term operational tolerance. CONCLUSION: We report on a series of patients with resolved PTLDs demonstrating long-term recurrence-free survival, of whom most experienced a long period of operational graft tolerance. IL-18 seems to play a role in the resolution of the PTLDs. Five patients underwent retransplantation with standard immunosuppression without recurrence. A previous diagnosis of PTLD should not be regarded as a contraindication for later retransplantation.
机译:背景:移植后的淋巴增生性疾病(PTLD)可通过减少或停止免疫抑制来解决,在许多移植患者中,此后许多移植物由于某种形式的操作耐受性而继续发挥功能。当移植物功能恶化时,可以选择再移植。细胞因子如白介素(IL)-10和IL-18可能在PTLD耐受性诱导和肿瘤消退中起作用。我们报告了一系列接受肾脏移植并证实为PTLD并且能够进行IL-18分析的患者的移植耐受性持续时间和再移植过程的长期随访。结果:PTLD诊断后对患者进行了长达7年的随访。对于明显的单形性淋巴瘤,治疗包括通过放射疗法停止免疫抑制。所有患者的PTLDs均得到解决,除一名患者(已移除其移植物)外,所有患者均表现出最高5年的手术移植耐受性。 5例患者进行了移植,直到移植后3年都没有PTLD复发的迹象。在分析的八名患者中,长期操作耐受性患者在PTLD消退和随访期间IL-18显着增加。结论:我们报道了一系列PTLDs已解决的患者,这些患者表现出长期无复发生存,其中大多数经历了长期的手术耐受性。 IL-18似乎在PTLD的解析中起作用。五例患者接受了标准免疫抑制的移植,无复发。先前对PTLD的诊断不应视为以后再移植的禁忌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号